Quick Answer
Arcutis Biotherapeutics, Inc. reported Total Revenue of $376.07 million for the year ending 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +91.3% in Total Revenue from 2024 to 2025.
- This data is from Arcutis Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $0.00 | Q1 2023: $2.78 million | Q2 2023: $5.19 million | Q3 2023: $38.11 million | Q1 2024: $49.57 million | Q2 2024: $30.86 million | Q3 2024: $44.76 million | Q1 2025: $65.85 million | Q2 2025: $81.50 million | Q3 2025: $99.22 million.
- Over the full 4 years of available data (2022 to 2025), Arcutis Biotherapeutics, Inc.'s Total Revenue has grown by 10,102.7%.
- Historical annual values: Fiscal year 2025: $376.07 million | Fiscal year 2024: $196.54 million | Fiscal year 2023: $59.61 million | Fiscal year 2022: $3.69 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: